Apellis (APLS) stock slides 15% after $689 mln 2025 revenue preview at JPM conference
Apellis shares fell 14.7% to $23.29 after the company projected 2025 U.S. net product revenue of about $689 million and reported rising demand for SYFOVRE. EMPAVELI’s 2025 U.S. revenue is expected to reach $102 million. Management updates are expected at the J.P. Morgan Healthcare Conference.